Based on the characteristics of ADC drugs, we have summarized the process for conducting patent research on ADC drugs.

Axalbion Therapeutics Begins Phase 2 Trial for Chronic Cough by Administering AX-8, a New TRPM8 Agonist, to the First Patient.

Based on the characteristics of ADC drugs, we have summarized the process for conducting patent research on ADC drugs.

Zai Lab to Share Early Findings from Phase 1 Study of ZL-1218, a Potential Anti-CCR8 Antibody for Advanced Tumor Therapy, at ESMO Congress 2024.

Currently, 272 ADC drugs have been initiated for clinical trials globally. Excluding the market withdrawal of Belantamab mafodotin (Blenrep®), 14 approved ADC products remain available.

The European Commission greenlights RYBREVANT®▼ (amivantamab) alongside chemotherapy for adults with advanced EGFR-mutated NSCLC after previous treatments haven't worked.

Aug 30th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Tonix Pharmaceuticals partners with Bilthoven Biologicals to advance TNX-801 Mpox vaccine development.

Based on the characteristics of siRNA drugs, we have summarized the process for conducting patent research on siRNA drugs.

Ordspono™ (odronextamab) has received approval in the EU for treating relapsed or refractory follicular lymphoma and diffuse large B-cell lymphoma.

Based on the characteristics of siRNA drugs, we have summarized the process for conducting patent research on siRNA drugs.

This approval broadens the scope of the MACI® (autologous cultured chondrocytes on porcine collagen membrane) label.